BET inhibitors drive Natural Killer activation in non-small cell lung cancer via BRD4 and SMAD3
© 2024. The Author(s)..
Non-small-cell lung carcinoma (NSCLC) is the most common lung cancer and one of the pioneer tumors in which immunotherapy has radically changed patients' outcomes. However, several issues are emerging and their implementation is required to optimize immunotherapy-based protocols. In this work, we investigate the ability of the Bromodomain and Extra-Terminal protein inhibitors (BETi) to stimulate a proficient anti-tumor immune response toward NSCLC. By using in vitro, ex-vivo, and in vivo models, we demonstrate that these epigenetic drugs specifically enhance Natural Killer (NK) cell cytotoxicity. BETi down-regulate a large set of NK inhibitory receptors, including several immune checkpoints (ICs), that are direct targets of the transcriptional cooperation between the BET protein BRD4 and the transcription factor SMAD3. Overall, BETi orchestrate an epigenetic reprogramming that leads to increased recognition of tumor cells and the killing ability of NK cells. Our results unveil the opportunity to exploit and repurpose these drugs in combination with immunotherapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Nature communications - 15(2024), 1 vom: 22. März, Seite 2567 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Reggiani, Francesca [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antineoplastic Agents |
|---|
| Anmerkungen: |
Date Completed 25.03.2024 Date Revised 25.03.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41467-024-46778-8 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370090349 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370090349 | ||
| 003 | DE-627 | ||
| 005 | 20240325235552.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240324s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41467-024-46778-8 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1347.xml |
| 035 | |a (DE-627)NLM370090349 | ||
| 035 | |a (NLM)38519469 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Reggiani, Francesca |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a BET inhibitors drive Natural Killer activation in non-small cell lung cancer via BRD4 and SMAD3 |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.03.2024 | ||
| 500 | |a Date Revised 25.03.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a Non-small-cell lung carcinoma (NSCLC) is the most common lung cancer and one of the pioneer tumors in which immunotherapy has radically changed patients' outcomes. However, several issues are emerging and their implementation is required to optimize immunotherapy-based protocols. In this work, we investigate the ability of the Bromodomain and Extra-Terminal protein inhibitors (BETi) to stimulate a proficient anti-tumor immune response toward NSCLC. By using in vitro, ex-vivo, and in vivo models, we demonstrate that these epigenetic drugs specifically enhance Natural Killer (NK) cell cytotoxicity. BETi down-regulate a large set of NK inhibitory receptors, including several immune checkpoints (ICs), that are direct targets of the transcriptional cooperation between the BET protein BRD4 and the transcription factor SMAD3. Overall, BETi orchestrate an epigenetic reprogramming that leads to increased recognition of tumor cells and the killing ability of NK cells. Our results unveil the opportunity to exploit and repurpose these drugs in combination with immunotherapy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Nuclear Proteins |2 NLM | |
| 650 | 7 | |a Transcription Factors |2 NLM | |
| 650 | 7 | |a Cell Cycle Proteins |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a SMAD3 protein, human |2 NLM | |
| 650 | 7 | |a Smad3 Protein |2 NLM | |
| 650 | 7 | |a BRD4 protein, human |2 NLM | |
| 650 | 7 | |a Bromodomain Containing Proteins |2 NLM | |
| 700 | 1 | |a Talarico, Giovanna |e verfasserin |4 aut | |
| 700 | 1 | |a Gobbi, Giulia |e verfasserin |4 aut | |
| 700 | 1 | |a Sauta, Elisabetta |e verfasserin |4 aut | |
| 700 | 1 | |a Torricelli, Federica |e verfasserin |4 aut | |
| 700 | 1 | |a Manicardi, Veronica |e verfasserin |4 aut | |
| 700 | 1 | |a Zanetti, Eleonora |e verfasserin |4 aut | |
| 700 | 1 | |a Orecchioni, Stefania |e verfasserin |4 aut | |
| 700 | 1 | |a Falvo, Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a Piana, Simonetta |e verfasserin |4 aut | |
| 700 | 1 | |a Lococo, Filippo |e verfasserin |4 aut | |
| 700 | 1 | |a Paci, Massimiliano |e verfasserin |4 aut | |
| 700 | 1 | |a Bertolini, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Ciarrocchi, Alessia |e verfasserin |4 aut | |
| 700 | 1 | |a Sancisi, Valentina |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nature communications |d 2010 |g 15(2024), 1 vom: 22. März, Seite 2567 |w (DE-627)NLM199274525 |x 2041-1723 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2024 |g number:1 |g day:22 |g month:03 |g pages:2567 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41467-024-46778-8 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2024 |e 1 |b 22 |c 03 |h 2567 | ||